SCHEDULE: CVI Investments Reports 9.9% Stake in Processa Pharma

CVI Investments, managed by Heights Capital Management, has reported a 9.9% beneficial ownership stake in Processa Pharmaceuticals, Inc. through warrants.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (Reporting Persons) beneficially own 4,471,067 shares of Processa Pharmaceuticals, Inc. common stock.
• This ownership represents 9.9% of Processa Pharmaceuticals, Inc.'s outstanding common stock.
• The reported shares are issuable upon the exercise of warrants.
• Warrants are not exercisable to the extent that beneficial ownership would exceed 9.99%.
• As of June 30, 2025, Processa Pharmaceuticals, Inc. had 40,284,356 shares outstanding, as indicated in their Form 10-Q filed on August 7, 2025.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and may exercise shared voting and dispositive power over the shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by institutional entities, which can be viewed as a positive signal of investor interest, though it does not provide operational or financial performance updates.

Positives

• A significant institutional investor, CVI Investments, Inc., holds a substantial 9.9% stake, potentially indicating confidence in Processa Pharmaceuticals, Inc.

Negatives

• No specific negative financial or operational details are disclosed in this ownership filing.

Risks

• Warrants held by CVI Investments, Inc. are subject to a limitation, not exercisable if beneficial ownership would exceed 9.99%, which restricts immediate full conversion.

Future Outlook

The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing the control of Processa Pharmaceuticals, Inc., indicating a passive investment strategy.

Management Comments

• No direct management comments from Processa Pharmaceuticals, Inc. are included in this filing.

Industry Context

This filing indicates a significant passive investment by institutional entities in a pharmaceutical company, which is common for investors seeking exposure to the biotech sector.

Comparison to Industry Standards

• Not applicable as this filing is an ownership disclosure, not a performance report.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability or perceived validation for the company's stock.

Next Steps

• Continued passive holding of the reported shares and warrants by the reporting persons.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant passive ownership stake by CVI Investments, Inc. and Heights Capital Management, Inc. in Processa Pharmaceuticals, Inc. While the substantial institutional holding (9.9%) could be interpreted as a vote of confidence, the filing itself does not contain operational performance data, financial results, or strategic updates that would warrant a 'buy' or 'sell' recommendation. The investment is stated to be passive, not for control influence. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new fundamental information to change an existing investment thesis, but confirms significant institutional interest.

Keywords

Processa Pharmaceuticals, CVI Investments, Heights Capital Management, Schedule 13G, beneficial ownership, common stock, warrants, pharmaceutical, biotech, investment